Article ID Journal Published Year Pages File Type
5590807 Multiple Sclerosis and Related Disorders 2017 7 Pages PDF
Abstract
Treatment with alemtuzumab induces neutropenia, which is mild in the large majority of pwMS treated. Leucocyte levels following alemtuzumab should be monitored as a marker of efficacy and safety; persistent neutropenia may require treatment.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Genetics
Preview
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment
Authors
, , ,